Vadastuximab is a novel antibody-drug molecule representing a crucial advancement in the management of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a antigen frequently https://dirstop.com/story28269729/vadastuximab-a-deep-investigation-into-cd33-specific-therapy